No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Securities purchased after the First Closing Date, each Option Closing Date, in the judgment of the Representative there shall not have occurred any Material Adverse Change.
Appears in 6 contracts
Samples: Underwriting Agreement (AMCI Acquisition Corp. II), Underwriting Agreement (AMCI Acquisition Corp. II), Underwriting Agreement (AMCI Acquisition Corp.)
No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Option Securities purchased after the First Closing Date, each Option Closing Date, in the judgment of the Representative there shall not have occurred any material adverse change in the authorized capital stock of the Company or any Material Adverse ChangeEffect or any development that would cause a Material Adverse Effect.
Appears in 6 contracts
Samples: Underwriting Agreement (Phio Pharmaceuticals Corp.), Underwriting Agreement (Vaxart, Inc.), Underwriting Agreement (Phio Pharmaceuticals Corp.)
No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Securities Shares purchased after the First Closing Date, each Option Closing Date, in the judgment of the Representative there shall not have occurred any Material Adverse Change.
Appears in 6 contracts
Samples: Underwriting Agreement (Mirati Therapeutics, Inc.), Underwriting Agreement (ACM Research, Inc.), Underwriting Agreement (Mirati Therapeutics, Inc.)
No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Securities Shares purchased after the First Closing Date, each Option Closing Date, in the judgment of the Representative Representatives there shall not have occurred any Material Adverse Change.
Appears in 5 contracts
Samples: Underwriting Agreement (Mirati Therapeutics, Inc.), Underwriting Agreement (Mirati Therapeutics, Inc.), Underwriting Agreement (Cidara Therapeutics, Inc.)
No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Securities Option Shares purchased after the First Closing Date, each Option Closing Date, in the judgment of the Representative there shall not have occurred any material adverse change in the authorized capital stock of the Company or any Material Adverse ChangeEffect or any development that would cause a Material Adverse Effect.
Appears in 3 contracts
Samples: Underwriting Agreement (Navidea Biopharmaceuticals, Inc.), Underwriting Agreement (InspireMD, Inc.), Underwriting Agreement (InspireMD, Inc.)
No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Securities purchased after the First Closing Date, each Option Closing Date, in the judgment of the Representative there shall not have occurred any material adverse change in the authorized capital stock of the Company or any Material Adverse ChangeEffect or any development that would cause a Material Adverse Effect.
Appears in 3 contracts
Samples: Underwriting Agreement (Bio-Path Holdings Inc), Underwriting Agreement (RXi Pharmaceuticals Corp), Underwriting Agreement (InspireMD, Inc.)
No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Securities Option Shares purchased after the First Closing Date, each Option Closing Date, in the judgment of the Representative there shall not have occurred any material adverse change in the authorized capital stock of the Company or any Material Adverse ChangeEffect or any development that would cause a Material Adverse Effect.
Appears in 1 contract
Samples: Lock Up Agreement (Vaxart, Inc.)
